3 completed, 1 terminated, 1 unknown. 3 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow NC-6004: new trials by email Literature Review of NC-6004 trials Research Report on NC-6004
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen NC-6004, Pembrolizumab - SCCHN | Phase 2 | Unknown | NanoCarrier Co., Ltd. | 136 | 2019-07-01 | 2021-03-17 |
| NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck NC-6004, Cetuximab, 5-FU - Carcinoma, Squamous Cell of Head and Neck | Phase 1 / Phase 2 | Completed | NanoCarrier Co., Ltd. | 1 | 2017-03-01 | 2019-04-29 |
| Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer NC-6004, Cetuximab, 5-FU - Head and Neck Neoplasms | Phase 1 | Terminated | Orient Europharma Co., Ltd. | 4 | 2016-06-01 | 2021-04-30 |
| Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer NC-6004, Gemcitabine - Solid Tumors | Phase 1 / Phase 2 | Completed | NanoCarrier Co., Ltd. | 119 | 2014-05-01 | 2025-01-22 |
| Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer NC-6004, Gemcitabine - Pancreatic Neoplasms | Phase 3 | Completed | Orient Europharma Co., Ltd. | 310 | 2014-01-01 | 2020-04-15 |
Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
NanoCarrier Co., Ltd. (3) · Orient Europharma Co., Ltd. (2)
Taiwan (3) · Bulgaria (2) · Hungary (2) · Poland (2) · Romania (2) · United States (2) · Croatia (1) · Czechia (1) · Hong Kong (1) · Italy (1) · Japan (1) · Malaysia (1) · Philippines (1) · Russia (1) · Serbia (1)
Atsushi Osada (1) · Atsushi Osada, Study Director (1) · Joao da Silva, MD (1) · Li-Tzong Chen, M.D., Ph. D. (1) · Ruey-Long Hong, MD PhD (1)